Clinical Trial

Correlation Between Circulating Fibroblast Activation Protein (FAP) and Fibrosis in Two Diseases (Rheumatoid Arthritis and Systemic Sclerosis)

Study acronym: FAP
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to measure a blood protein called fibroblast activation protein (FAP), which is linked to tissue scarring and inflammation. A small blood sample will be taken from participants (RA , SSc patients and healthy people ), and the FAP level will be measured and compared with routine clinical examinations, imaging studies, and lung function tests. The purpose of this study is to improve understanding of disease activity and lung involvement in these conditions and to explore whether FAP could be useful as a blood marker for future patients. Participation in this study will not change the participant's usual medical care.
Trial Details
NCT Number NCT07393217
Lead Sponsor Sohag University
Conditions Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)
Enrollment 111 participants
Start Date 2026-03-01
Primary Completion 2027-03-01 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-02-06